HPV vaccine for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial aims to develop a vaccine that trains your immune system to fight HPV, the virus that causes cervical cancer. By studying your blood, researchers hope to find better ways to prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between the ages of 18 and 65.
- You must have cervical cancer caused by HPV type 16 or 18.
- Your cancer must be at a stage between IB1 and IV (from early to advanced).
- You must be able to receive standard treatment, such as surgery alone, or surgery plus radiation and chemotherapy.
- You cannot have any other type of cancer or severe uncontrolled medical conditions (like active infections, heart problems, or diabetes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This study tests an experimental vaccine (RG002) for women with cervical pre-cancer caused by HPV types 16 or 18. The vaccine is designed to help the body fight the virus and potentially clear the pre-cancerous cells, possibly avoiding more invasive treatments.
This trial tests whether a vaccine against HPV can help prevent pre-cancerous lesions from coming back after you've had them. It's for people who have had high-grade pre-cancerous lesions but haven't yet been treated for them.
This trial tests two experimental vaccines to boost the immune system against HPV 16. Healthy relatives of patients with HPV 16 cancer receive the vaccines, then donate blood cells for research.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.